Jula Inrig
Net worth: 7 M $ as of 2026-08-30
Net worth: 7 M $ as of 2026-08-30
Jula Inrig is currently Chief Medical Officer, EVP-Research & Development at Travere Therapeutics, Inc., starting in 2026.
Former positions include Director at Kidney Health Initiative from 2013 to 2018 and Global Head-Renal Center of Excellence at IQVIA, Inc. from 2017 to 2021.
Education includes undergraduate studies at California State University-Sacramento, a doctorate from Loma Linda University, and graduate studies at Duke University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-21 | 112,770 ( 0.12% ) | 7 M $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| TRAVERE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-01-03 |
| Companies | Position | End |
|---|---|---|
| IMS HEALTH, INC. | Corporate Officer/Principal | 2021-11-30 |
Kidney Health Initiative | Director/Board Member | 2017-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
IQVIA, Inc.
IQVIA, Inc. Packaged SoftwareTechnology Services Provides AI assistant, analytics and clinical research services for healthcare sector | Technology Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
California State University-Sacramento
California State University-Sacramento Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loma Linda University
Loma Linda University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Travere Therapeutics, Inc.
Travere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in developing and delivering life-changing therapies to people living with rare kidney, liver & metabolic diseases | Health Technology |
Kidney Health Initiative |
Select your edition
All financial news and data tailored to specific country editions